Smoking is associated with age at disease onset in Parkinson's disease

Rosas, Irene; Morís, Germán; Coto, Eliécer; Blázquez-Estrada, Marta; Suárez, Emma; García-Fernández, Ciara; Martı́nez, Carmen; Duarte-Herrera, Israel David; Pérez-Oliveira, Sergio; Adarmes‐Gómez, Astrid; Aguilar, Miquel; Barrero, Francisco Javier; Yarza, Jesús Alberto Bergareche; Bonilla-Toribio, Marta; Botía, Juan A.; Boungiorno, María Teresa; Buiza‐Rueda, Dolores; Cámara, Ana; Carrillo, Fátima; Cerdan, Debora; Clarimón, Jordi; Compta, Yaroslau; Díez-Fairén, Mónica; Dols‐Icardo, Oriol; Fábregues, Oriol de; Cartagena, Pilar Sanz; Duarte, Jacinto; Durán, Raquel; Escamilla‐Sevilla, Francisco; Ezquerra, Mario; Feliz, Cici; Fernández‐Santiago, Rubén; Fernández, Manel; García‐Ruiz, Pedro J.; Gómez‐Garre, Pilar; Heredia, Maria Jose Gómez; Gorostidi, Ana; Hoenicka, Janet; Infante, Jon; Jesús, Silvia; Jiménez‐Escrig, Adriano; Kulisevsky, Jaime; Labrador‐Espinosa, Miguel A.; López‐Sendón, José; Munáin, Adolfo López de; Macías‐García, Daniel; Martínez‐Torres, Irene; Marín, Juan; Martı́, Marı́a José; Martínez‐Castrillo, Juan Carlos; Álvarez-Santullano, Marina Mata; Mínguez-Castellanos, Adolfo; Mir, Pablo; Rezola, Elisabet Mondragón; Muñoz, Esteban; Pagonabarraga, Javier; Pástor, Pau; Errázquin, Francisco; Periñán, María Teresa; Ruíz‐Martínez, Javier; Ruz, Clara; Rodríguez, A; Sierra, María; Tabernero, C; Tartari, Juan Pablo; Tolosa, Eduard; Valldeoriola, Francesc; Vela, Lydia; Vives, Francisco; Pascual‐Sedano, Berta; Hernández‐Vara, Jorge; Rolán, Dolores Vilas; Bandrés‐Ciga, Sara; Álvarez, Victoria; Menéndez-González, Manuel

doi:10.1016/j.parkreldis.2022.03.005

Cited by 5 publications

(2 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, APOE ε4 has been linked to hallucinations and delusions in AD patients [ 89 ], and may be also an age-related risk factor for the worsening of delusions and hallucinations in patients with schizophrenia [ 90 ]. In PD, the APOE ε4 allele has been also associated with earlier disease onset [ 91 , 92 ] and a greater risk of dementia [ 93 ], although there is also evidence that does not confirm these relationships [ 92 , 94 ]. Furthermore, APOE ε4 has been associated with increased severity of Lewy body pathology independent of AD pathology in another study, suggesting that APOE ε4 may promote the spreading of LBD [ 95 ].…”

Section: Genetic Architecture Of Psychosis In Parkinson’s Diseasementioning

confidence: 99%

Psychosis in Parkinson’s Disease: A Lesson from Genetics

Angelopoulou

Bougea

Papageorgiou

et al. 2022

Genes

View full text Add to dashboard Cite

Psychosis in Parkinson’s disease (PDP) represents a common and debilitating condition that complicates Parkinson’s disease (PD), mainly in the later stages. The spectrum of psychotic symptoms are heterogeneous, ranging from minor phenomena of mild illusions, passage hallucinations and sense of presence to severe psychosis consisting of visual hallucinations (and rarely, auditory and tactile or gustatory) and paranoid delusions. PDP is associated with increased caregiver stress, poorer quality of life for patients and carers, reduced survival and risk of institutionalization with a significant burden on the healthcare system. Although several risk factors for PDP development have been identified, such as aging, sleep disturbances, long history of PD, cognitive impairment, depression and visual disorders, the pathophysiology of psychosis in PD is complex and still insufficiently clarified. Additionally, several drugs used to treat PD can aggravate or even precipitate PDP. Herein, we reviewed and critically analyzed recent studies exploring the genetic architecture of psychosis in PD in order to further understand the pathophysiology of PDP, the risk factors as well as the most suitable therapeutic strategies.

show abstract

Section: Genetic Architecture Of Psychosis In Parkinson’s Diseasementioning

confidence: 99%

Psychosis in Parkinson’s Disease: A Lesson from Genetics

Angelopoulou

Bougea

Papageorgiou

et al. 2022

Genes

View full text Add to dashboard Cite

show abstract

“…In contrast, studies investigating the effect of environmental and lifestyle factors or gene-environment interactions on PD AAO are only sparse. While some studies found a protective effect of coffee and smoking on PD AAO 32 , 37 – 44 , literature on the effect of aspirin on AAO is lacking 32 . It also remains unclear how gene-environment interactions or a genetic predisposition to PD risk together with the presence of certain lifestyle factors influences the AAO in PD.…”

Section: Introductionmentioning

confidence: 99%

The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson’s disease

Gabbert,

Blöbaum,

Lüth

et al. 2024

Sci Rep

View full text Add to dashboard Cite

The objective of this study was to investigate the association between a Parkinson’s disease (PD)-specific polygenic score (PGS) and protective lifestyle factors on age at onset (AAO) in PD. We included data from 4367 patients with idiopathic PD, 159 patients with GBA1-PD, and 3090 healthy controls of European ancestry from AMP-PD, PPMI, and Fox Insight cohorts. The association between PGS and lifestyle factors on AAO was assessed with linear and Cox proportional hazards models. The PGS showed a negative association with AAO (β = − 1.07, p = 6 × 10–7) in patients with idiopathic PD. The use of one, two, or three of the protective lifestyle factors showed a reduction in the hazard ratio by 21% (p = 0.0001), 44% (p < 2 × 10–16), and 55% (p < 2 × 10–16), compared to no use. An additive effect of aspirin (β = 7.62, p = 9 × 10–7) and PGS (β = − 1.58, p = 0.0149) was found for AAO without an interaction (p = 0.9993) in the linear regressions, and similar effects were seen for tobacco. In contrast, no association between aspirin intake and AAO was found in GBA1-PD (p > 0.05). In our cohort, coffee, tobacco, aspirin, and PGS are independent predictors of PD AAO. Additionally, lifestyle factors seem to have a greater influence on AAO than common genetic risk variants with aspirin presenting the largest effect.

show abstract

Clinical characteristics and treatment of psychosis in Parkinson’s disease: A narrative review

Stamenović,

Živadinović,

Đurić

2024

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a chronic, progressive, neurodegenerative disorder whose clinical presentation consists of motor and non-motor signs and symptoms. Among the non-motor symptoms, psychosis can occur in the later stages of the disease. Psychosis in PD (PDP) is a common, complex, and significantly disabling disorder associated with poorer quality of life, accelerated cognitive decline, need for hospitalization or institutionalization, and mortality. Hallucinations are a significant symptom of PDP, sporadic at first but more frequent in the later course of the disease, and significantly disrupt daily activities. Appropriate and timely screening of psychotic manifestations is necessary for adequate therapeutic procedures. After the exclusion of comorbid conditions as a possible cause of psychosis, correction of antiparkinsonian therapy may be required, and if necessary, the introduction of antipsychotics. The latest therapeutic recommendations include the use of pimavanserin, if available, otherwise second-generation or atypical antipsychotics. Although PDP has long been recognized as a possible complication in the course of the disease, further clinical studies are needed to fully understand its etiopathogenesis and pathophysiological mechanisms.

show abstract

Smoking is associated with age at disease onset in Parkinson's disease

Cited by 5 publications

References 18 publications

Psychosis in Parkinson’s Disease: A Lesson from Genetics

Psychosis in Parkinson’s Disease: A Lesson from Genetics

The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson’s disease

Clinical characteristics and treatment of psychosis in Parkinson’s disease: A narrative review

Contact Info

Product

Resources

About